According to the Inspector General for Medicare, Medicare Part B spending could have been lowered 35% (saving $251 million) if prices for drugs like milrinone lactate and Hizentra had been updated to current standards instead of being based on decades-old, patent-protected prices.
Additionally, drugs that are used to treat life-threatening conditions such as cancer, diabetes, congestive heart failure and rheumatoid arthritis could have saved patients and insurance providers another $50 million. To make matters even worse, some providers were being reimbursed twice for their expenses, while patients continued to suffer physically and financially.
If you think it’s time to hold lawmakers and insurance companies accountable for unacceptable practices such as these, please Like & Share this post. You CAN make a difference.